Trial record 9 of 433 for:    PAH

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

This study has been terminated.
(Study closed due to limited availability of eligible subjects and competition by for enrollment by other studies)
Sponsor:
Information provided by (Responsible Party):
United Therapeutics
ClinicalTrials.gov Identifier:
NCT00439946
First received: February 22, 2007
Last updated: June 12, 2013
Last verified: June 2013
  Purpose

The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH). Unlike Flolan, Remodulin does not need to be mixed daily and is stable at room temperature, so there is no need for ice packs. In addition, Remodulin is changed every 48hrs, instead of every 12-24 (with ice packs) or every 8 hours (without ice packs) with Flolan. Flolan is given using a type of portable medication pump called the CADD Legacy infusion pump. In this study, Remodulin will be given using a smaller and lighter medication pump called the Crono Five infusion pump. This study will also assess the effect that changing to Remodulin will have on treatment satisfaction and patient quality of life.


Condition Intervention Phase
Pulmonary Arterial Hypertension
Drug: treprostinil
Device: Crono Five ambulatory pump
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) Using the Crono Five Ambulatory Infusion Pump in Patients With Stable Pulmonary Arterial Hypertension (PAH): Safety, Efficacy and Treatment Satisfaction

Resource links provided by NLM:


Further study details as provided by United Therapeutics:

Primary Outcome Measures:
  • Change From Baseline at Week 8 in 6-Minute Walk Distance (6MWD) [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The administration of the 6MWD test and specifications of the testing area were consistent with the American Thoracic Society guidelines and the usual practice of the investigative site [American Thoracic Society (ATS) guidelines; 2002].


Secondary Outcome Measures:
  • Change From Baseline at Week 8 in Borg Dyspnea Score Immediately After Six Minute Walk Test [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-Minute Walk Test. Scores range from 0 (for the best condition) to 10 (for the worst condition).

  • Change From Baseline at Week 8 in World Health Organization (WHO) Functional Classification [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    WHO functional class is a system to help clinicians determine how limited a patient is in their ability to do the activities of daily living. The scale ranges from class I to class IV. In general, patients with more severe Pulmonary Hypertension (PH) tend to have a higher functional class.

  • Change From Baseline at Week 8 in Symptoms of PAH- Fatigue [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.

  • Change From Baseline at Week 8 in Symptoms of PAH- Dyspnea [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.

  • Change From Baseline at Week 8 in Symptoms of PAH- Edema [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.

  • Change From Baseline at Week 8 in PAH Symptoms- Orthopnea [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.

  • Change From Baseline at Week 8 in PAH Symptoms- Dizziness [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.

  • Change From Baseline at Week 8 in PAH Symptoms- Syncope [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.

  • Change From Baseline at Week 8 in PAH Symptoms- Chest Pain [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.

  • Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    A Drug Administration Activities Diary, used by subjects to record in detail the amount of time (in minutes) spent on specifically-defined drug preparation/administration activities (e.g. diluting drug, preparing reservoir, and changing tubing), was completed over a 7-day period during the Screening period while on epoprostenol and repeated at Week 7 following transition to Remodulin.

  • Change From Baseline at Week 8 in Score on Quality of Life (QOL) Questionnaire - The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) [ Time Frame: Baseline and Week 8 ] [ Designated as safety issue: No ]
    The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), a validated PAH-specific instrument consisting of 65 items used to assess symptoms, functioning and QOL. The CAMPHOR was completed at Baseline and at Week 8. The CAMPHOR consists of 3 scales: 1. A 25-item overall symptoms scale scored 0-25, with a higher score indicating the presence of more symptoms. 2. A 15 item Activity/Functioning scale scored 0-30, where a low score indicates good functioning. 3. A 25-item QoL scale scored 0-25, with a high score indicating poor QoL. Additionally, a total score was recorded by adding up the the scores from the 3 above scales. The Symptom and QoL scales have dichotomous ('True'/'Not true') response options while the Activity/Functioning scale has three-point ('Able to do on own without difficulty'/'Able to do on own with difficulty'/'Unable to do on own') response options. Reduction in score denotes improved heath status.

  • Change From Baseline at Week 8 in Score on Treatment Satisfaction Questionnaire- The Treatment Satisfaction Questionnaire for Medication (TSQM) [ Time Frame: Baseline and Week 8 ] [ Designated as safety issue: No ]
    The Treatment Satisfaction Questionnaire for Medication (TSQM), a validated generic measure of treatment satisfaction consisting of 14 Likert-response items comprising four domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. The TSQM was completed at baseline and at Week 8. The TSQM consists of 13 items that made up three specific scales (Effectiveness, Side effects, Convenience) and one global satisfaction scale. TSQM items are scaled using either a 5-point or 7-point scale. Five-point scales are used for unidimensional continua (e.g. extremely satisfied to not at all), while 7-point scales are used for bipolar continua (e.g., extremely positive to extremely negative. Non-neutral midpoints are used for 7-point scales, resulting in a greater range of positive response options than negative options for these items. Scale scores are transformed into scores ranging from 0 to 100, with a higher score indicating more satisfaction.

  • Subject Responses to the Patient Impression of Change Questionnaire (Administered at Week 8 Only) [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    A Patient Global Impression of Change Questionnaire, which consists of three items that ask the subject to rate changes (much better, somewhat better, about the same, somewhat worse, much worse) in their symptoms of PAH, the amount of time spent on activities associated with preparing and administering PAH therapy, and their satisfaction with their PAH therapy since transitioning from epoprostenol to intravenous Remodulin was conducted at Week 8 only and responses are reported as frequency distributions.


Enrollment: 8
Study Start Date: February 2007
Study Completion Date: March 2011
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: treprostinil
IV treprostinil continuous infusion via Crono Five infusion pump.
Drug: treprostinil
rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
Other Name: Remodulin
Device: Crono Five ambulatory pump
Used for administration of IV Remodulin (treprostinil)

Detailed Description:

Pulmonary arterial hypertension (PAH), which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading to inactivity and death. The goal of PAH treatment is to lengthen survival time, to ameliorate symptoms of PAH, and to improve health related quality of life (HRQOL).

Remodulin® (treprostinil sodium), a stable analogue of prostacyclin, possesses potent pulmonary and systemic vasodilatory and platelet anti-aggregatory actions in vitro and in vivo. Recently, Remodulin received FDA approval for intravenous therapy based upon bioequivalence of the intravenous (IV) and subcutaneous (SC) routes of administration. Remodulin is more chemically stable than epoprostenol and may offer potential safety and convenience advantages compared to intravenous epoprostenol that may impact Health Related Quality of Life (HRQOL) and/or patient satisfaction. Unlike epoprostenol, Remodulin does not need to be mixed daily and is stable at room temperature eliminating the need for ice packs. Since Remodulin remains in the body longer than epoprostenol (4 hrs instead of less than 5 minutes) there is less risk of cardiovascular collapse from a sudden interruption of infusion, such as a line clog. In an open-label study in Europe, patients who were using a type of portable medication pump called the CADD Legacy pump were rapidly switched from Flolan to Remodulin with no serious side effects. This study will examine effects of switching from therapy with epoprostenol or Flolan to IV Remodulin and compare changes in HRQOL and treatment satisfaction before and after rapid switch from epoprostenol to Remodulin in patients with pulmonary hypertension from the CADD legacy pump to a smaller pump called the Crono Five.

Participation in this study will last approximately 10 weeks. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, exercise tests and patient questionnaires. Participants will have 4 visits during the study and will spend at least 1 night in the hospital.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 to 65 years
  • Diagnosis of one of the following WHO Classifications of pulmonary hypertension:

    1. Group 1 pulmonary arterial hypertension

      • Idiopathic pulmonary arterial hypertension (IPAH)
      • Familial pulmonary arterial hypertension (FPAH)
      • Associated pulmonary arterial hypertension (APAH):

        1. collagen vascular disease
        2. congenital systemic-to-pulmonary shunt repaired greater than 5 years prior to study entry.
        3. portal hypertension
        4. drugs and toxins
    2. Group 4 pulmonary hypertension due to chronic thromboembolic pulmonary hypertension (CTEPH)
  • WHO Class II-III
  • Currently receiving intravenous epoprostenol therapy for at least three months and a stable dose for at least one month.
  • Have central intravenous catheter
  • Optimally treated with conventional pulmonary hypertension therapy and clinically stable for at least one month.
  • Mentally and physically capable of learning to administer Remodulin using an intravenous infusion pump.

Exclusion Criteria:

  • nursing or pregnant woman
  • received a new type of chronic therapy (including but not limited to oxygen, a different category of vasodilator, a diuretic, digoxin, bosentan, sildenafil) for pulmonary hypertension added within the last month.
  • Had any PAH medication discontinued within the week prior to study entry.
  • Received any prostacyclin or prostacyclin analog except epoprostenol in the past 3 months.
  • Had a central venous line infection within the past 30 days.
  • Previous documented evidence of significant parenchymal lung disease as evidenced by pulmonary function tests as follows (any one of the following):

    1. Total Lung Capacity ≤ 60% (predicted) or
    2. If Total Lung Capacity is between 60% and 70% (predicted), a High Resolution Computed Tomography (CT) scan must be performed to rule out diffuse interstitial fibrosis or alveolitis
  • History of or evidence of left-sided heart disease
  • Having any other disease that is associated with pulmonary hypertension (e.g. sickle cell anemia, schistosomiasis).
  • Having a musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease, which is thought to limit ambulation, or be connected to a machine, which is not portable.
  • Uncontrolled systemic hypertension as evidenced by a systolic blood pressure greater than 160 millimeters of mercury (mmHg) or diastolic blood pressure greater than 100 mmHg.
  • Chronic renal insufficiency as defined by serum creatinine greater than 2.5 milligrams per deciliter (mg/dL) or the requirement for dialysis.
  • Receiving an investigational drug, have in place an investigational device, or have participated in an investigational drug study within the past 30 days.
  • Active infection, or any other ongoing condition that would interfere with the interpretation of study assessments.
  • The presence of any physiological or psychological condition that contraindicates the administration of Remodulin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00439946

Locations
United States, California
University of California San Francisco (UCSF) Medical Center
San Francisco, California, United States, 94143
United States, New York
THE NEW YORK-PRESBYTERIAN HOSPITAL Weill Cornell Medical Center
New York, New York, United States, 10065
United States, Oklahoma
Integris Baptist Medical Center
Oklahoma City, Oklahoma, United States, 73122
Sponsors and Collaborators
United Therapeutics
Investigators
Principal Investigator: Remzi Bag, MD INTEGRIS Baptist Medical Center
Principal Investigator: Evelyn Horn, MD Weill Medical College of Cornell University
Principal Investigator: Teresa DeMarco, MD University of California, San Francisco
  More Information

No publications provided

Responsible Party: United Therapeutics
ClinicalTrials.gov Identifier: NCT00439946     History of Changes
Other Study ID Numbers: RIV-PH-410
Study First Received: February 22, 2007
Results First Received: March 26, 2013
Last Updated: June 12, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by United Therapeutics:
pulmonary hypertension
PAH
Remodulin
treprostinil
Quality of Life
rapid switch

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Treprostinil
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 19, 2014